- PR Newswire•4 days agoFive-Year Open-Label Prospective Study Data Presented at the 12th Congress of European Crohn's and Colitis Organisation (ECCO) Provides Information on the Long-Term Use of Vedolizumab in Adult Patients with Moderate to Severely Active Ulcerative Colitis and Crohn's Disease
OSAKA, Japan, Feb. 17, 2017 /PRNewswire/ -- Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") today announced that interim findings from the ongoing, open-label GEMINI long-term safety (LTS) study were presented during the 12th Congress of European Crohn's and Colitis Organisation (ECCO) in Barcelona, Spain, February 15-18, 2017. Data presented from two five-year interim analyses of effectiveness and safety in patients with moderate to severely active ulcerative colitis (UC) and Crohn's disease (CD) indicated that long-term treatment of vedolizumab in responders was associated with long-term clinical response and remission, in addition to health-related quality of life (HRQL) improvements for patients over a five-year period.
- American City Business Journals•5 days ago
Following a partnership announced in September , Raleigh-based contract research organization PRA Health Sciences and pharmaceutical giant Takeda Pharmaceutical Company Limited have expanded their deal to Japan. PRA (PRAH) and Takeda (TKPHF) will form a joint venture for the deal’s expansion, which they will each hold 50 percent of, the companies announced. The joint venture will focus on clinical trials and drug safety services.
- Zacks•11 days ago
Seattle Genetics, Inc (SGEN) reported a loss of 39 cents per share, wider than the Zacks Consensus Estimate of a loss of 34 cents and wider than the year-ago loss of 18 cents.
TKPYY : Summary for TAKEDA PHARMA - Yahoo Finance
Takeda Pharmaceutical Company Limited (TKPYY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||23.01 - 23.11|
|52 Week Range||19.96 - 25.15|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||30.69|
|Dividend & Yield||0.78 (3.40%)|
|1y Target Est||N/A|